They found that 11.9% of the study population switched to TAF/FTC in the first year it was available. The team evaluated how many PrEP users switched to TAF/FTC and whether patients had a clinical indication for switching. Generic TDF/FTC could revolutionize PrEP access, but that opportunity will be missed if resources are invested in a far more expensive medication without proportional improvements in clinical outcomes. All patients were seen at Fenway Health, a Boston community health center that specializes in care for sexual and gender minorities. The researchers extracted electronic health record data from 2,892 adults who were assigned male sex at birth, were prescribed TDF/FTC for PrEP in the year before FDA approval of TAF/FTC, and had at least one PrEP prescription in the following year. “Generic TDF/FTC could revolutionize PrEP access, but that opportunity will be missed if resources are invested in a far more expensive medication without proportional improvements in clinical outcomes.” has been cost, including both perceived and actual costs,” said lead author Julia Marcus, PhD, Associate Professor in the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute. “One of the most critical barriers to broad and equitable PrEP use in the U.S. in October 2020, and now costs as low as $30 per month, compared with about $1800 per month for branded TAF/FTC.
The medications differ substantially, however, when it comes to price: generic TDF/FTC became available in the U.S. TDF/FTC has been associated with small decreases in renal function and bone mineral density, and TAF/FTC has been associated with minor weight gain and dyslipidemia, but these incremental differences have not translated to differences in adverse clinical events. TAF/FTC was approved by the FDA in 2019 for preventing sexual transmission of HIV, except for people at risk through receptive vaginal sex.īoth PrEP medications are highly effective and extremely safe. It is available in two forms: co-formulated tenofovir disoproxil fumarate and emtricitabine (TDF/FTC, or Truvada) and the newer tenofovir alafenamide with emtricitabine (TAF/FTC, or Descovy).
PrEP is an antiretroviral pill that is 99% effective in preventing HIV acquisition when taken as prescribed. The study was led by researchers at Harvard Medical School, Harvard Pilgrim Health Care Institute, and The Fenway Institute, and appears online as an Editor’s Choice article in Open Forum Infectious Diseases. Study results indicate that a minority of those who switched had a documented clinical reason to do so.
#Prep medication trial#
Promotion of Breastfeeding Intervention Trial (PROBIT).Chronic Disease Research Across the Lifecourse.Center for Healthcare Research in Pediatrics.
0 kommentar(er)
